PATHOGENESIS OF ACQUIRED RENAL CYSTIC DISEASE OF THE KIDNEYS WITH TUMOR GENESIS -EXPERIMENTAL STUDY-

获得性肾囊性肾病与肿瘤发生的发病机制-实验研究-

基本信息

  • 批准号:
    09671633
  • 负责人:
  • 金额:
    $ 1.73万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1999
  • 项目状态:
    已结题

项目摘要

Haemodialysis improved the prognosis of CRF patients. But acquired cystic disease of kidney (ACDK) occurred in original kidneys in long survival cases, which have higher rates of the incidence of renal cell carcinoma(RCC). Whenever it is thought that mucous membranes of ACDK acquired the ability of growth and become to adenocarcinoma through adenoma, its mechanism is still in the dark. In our study we tried to make Rat-ACDK models and researched the roles of the growth factors on its mechanism. 50 SD rats (6 week) were divided into 4 groups. Group A : Control. Group B : forced to intake OXCa 50g cach orally to make ACDK, Group C : forced to drink streptozotocin(SZ) 0.6g each in water to make RCC, Group D : OXCa 50g and SZ 0.6g were fed. 90 days later we gamed the rats and compared with them using HE stained, immunohistochemical stained (cytokeratin and bimentin) and TUNEL stained tissues. As a result we could made renal cysts on Group B and D.But the cysts didn't have RCC.
血液透析改善了CRF患者的预后。但获得性囊性肾病(ACDK)发生在存活时间较长的原发肾,是肾细胞癌(RCC)发生率较高的病例。以往认为ACDK的粘膜是通过腺瘤获得生长能力而发展为腺癌的,但其发生机制尚不清楚。本研究尝试建立大鼠ACDK模型,探讨生长因子在其发病机制中的作用。6周龄SD大鼠50只,随机分为4组。A组:对照组。B组:C组:灌服链脲佐菌素(SZ)0.6g/只,制备RCC; D组:灌服OXCa 50 g和SZ 0.6g。90天后处死动物,取组织行HE染色、免疫组化染色(细胞角蛋白和bimentin)和TUNEL染色。结果:B、D组均能形成肾囊肿,但囊肿内无肾细胞癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
藤田 潔: "腫瘍発生を伴う多嚢化萎縮腎モデルの作成および増殖因子の作用機序に関する研究"新薬と臨症. 50. 267-271 (2001)
Kiyoshi Fujita:“伴随肿瘤发展的多囊性萎缩肾模型的创建和生长因子作用机制的研究”《新药与临床状况》50. 267-271 (2001)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FUJITA Kiyoshi其他文献

FUJITA Kiyoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FUJITA Kiyoshi', 18)}}的其他基金

A study of electirical properties of rock associated with dehydrationn and melt
与脱水和熔融相关的岩石电特性研究
  • 批准号:
    24540512
  • 财政年份:
    2012
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Electrical conductivity measurements of hydrous mineral and hydrous rock
含水矿物和含水岩石的电导率测量
  • 批准号:
    19540507
  • 财政年份:
    2007
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Measurement of Electrical Conductivity within the crust and its anisotropy
地壳内电导率及其各向异性的测量
  • 批准号:
    16540387
  • 财政年份:
    2004
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of Thomsen-Friedenreich Antigen in Human Bladder Tumors as Detected by Specific Antibody.
通过特异性抗体检测人膀胱肿瘤中 Thomsen-Friedenreich 抗原的研究。
  • 批准号:
    60570752
  • 财政年份:
    1985
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Combination therapy for renal cell carcinoma using oncolytic virus G47d
使用溶瘤病毒 G47d 联合治疗肾细胞癌
  • 批准号:
    23K08752
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sensitization to RIPK1-dependent death as a strategy to enhance response of renal cell carcinoma (RCC) to immunotherapy
对 RIPK1 依赖性死亡的敏感性作为增强肾细胞癌 (RCC) 对免疫治疗反应的策略
  • 批准号:
    10721156
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
Association between efficacy of Immuno-Oncology combination therapy for renal cell carcinoma and gut microbiota including fungi and viruses
肾细胞癌免疫肿瘤联合疗法的疗效与肠道微生物群(包括真菌和病毒)之间的关联
  • 批准号:
    23K08749
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
研究 KEAP1 种系和体细胞突变在肾细胞癌中的作用
  • 批准号:
    10740481
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma
RNA去甲基化酶FTO在肾细胞癌代谢重编程中的作用
  • 批准号:
    10659085
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
SETD2 在肾细胞癌中的合成致死靶向
  • 批准号:
    10607320
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
Targeting PRMT1 in Clear Cell Renal Cell Carcinoma
透明细胞肾细胞癌中的靶向 PRMT1
  • 批准号:
    488615
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
    Operating Grants
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
MiT/TFE 易位肾细胞癌中激活的 NRF2 信号传导的分子机制和治疗靶向
  • 批准号:
    10633699
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
Elucidating the Understudied Kinase PNCK as a Prospective Drug Target in Renal Cell Carcinoma
阐明正在研究的激酶 PNCK 作为肾细胞癌的潜在药物靶点
  • 批准号:
    10667043
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
Pro-tumorigenic roles of a VHL isoform in Clear Cell Renal Cell Carcinoma
VHL 亚型在透明细胞肾细胞癌中的促肿瘤作用
  • 批准号:
    10649049
  • 财政年份:
    2023
  • 资助金额:
    $ 1.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了